Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Adv Ther. 2020 Nov;37(11):4755-4756. doi: 10.1007/s12325-020-01482-z.

Pietro Lampertico^{1

2}, Stefan Mauss³, Marcello Persico⁴, Stephen T Barclay^{5

6}, Steven Marx⁷, Kristina Lohmann⁸, Mark Bondin⁷, ZhenZhen Zhang⁷, Fiona Marra⁹, Pamela S Belperio¹⁰, Heiner Wedemeyer^{11

12

13}, Steven Flamm¹⁴

¹ Division of Gastroenterology and Hepatolgy, CRC "A.M. and A.Migliavacca" Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. pietro.lampertico@unimi.it.
² Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. pietro.lampertico@unimi.it.
³ Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
⁴ Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy.
⁵ Department of Life Sciences, Glasgow Caledonian University, Glasgow, UK.
⁶ Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
⁷ AbbVie Inc., North Chicago, IL, USA.
⁸ AbbVie Deutschland GmBH Co. KG, Wiesbaden, Germany.
⁹ University of Liverpool Hepatology Drug Interactions Group, Liverpool, UK.
¹⁰ Department of Veterans Affairs, VA Palo Alto Healthcare System, Palo Alto, CA, USA.
¹¹ Department of Gastroenterology and Hepatology, Essen University Hospital, Essen, Germany.
¹² Leberstiftungs-GmbH Deutschland, Hannover, Germany.
¹³ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
¹⁴ Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Abstract

In the original article, there is an error in Fig. 1.